JP6460796B2 - 高親和性ｓｉｒｐ−アルファ試薬 - Google Patents

高親和性ｓｉｒｐ−アルファ試薬 Download PDF

Info

Publication number
JP6460796B2
JP6460796B2 JP2014552401A JP2014552401A JP6460796B2 JP 6460796 B2 JP6460796 B2 JP 6460796B2 JP 2014552401 A JP2014552401 A JP 2014552401A JP 2014552401 A JP2014552401 A JP 2014552401A JP 6460796 B2 JP6460796 B2 JP 6460796B2
Authority
JP
Japan
Prior art keywords
sirpα
high affinity
cells
polypeptide variant
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014552401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504899A (ja
Inventor
マイケル リング，アーロン
マイケル リング，アーロン
クリストファー ガルシア，ケナン
クリストファー ガルシア，ケナン
アンドリュー ワイスコフ，キップ
アンドリュー ワイスコフ，キップ
エム． レビン，アロン
エム． レビン，アロン
エル． ワイスマン，アービング
エル． ワイスマン，アービング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2015504899A publication Critical patent/JP2015504899A/ja
Application granted granted Critical
Publication of JP6460796B2 publication Critical patent/JP6460796B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014552401A 2012-01-17 2013-01-17 高親和性ｓｉｒｐ−アルファ試薬 Active JP6460796B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261587247P 2012-01-17 2012-01-17
US61/587,247 2012-01-17
PCT/US2013/021937 WO2013109752A1 (en) 2012-01-17 2013-01-17 High affinity sirp-alpha reagents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017134728A Division JP6742279B2 (ja) 2012-01-17 2017-07-10 高親和性ｓｉｒｐ−アルファ試薬

Publications (2)

Publication Number Publication Date
JP2015504899A JP2015504899A (ja) 2015-02-16
JP6460796B2 true JP6460796B2 (ja) 2019-01-30

Family

ID=48799653

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014552401A Active JP6460796B2 (ja) 2012-01-17 2013-01-17 高親和性ｓｉｒｐ−アルファ試薬
JP2017134728A Active JP6742279B2 (ja) 2012-01-17 2017-07-10 高親和性ｓｉｒｐ−アルファ試薬
JP2019151758A Active JP6783361B2 (ja) 2012-01-17 2019-08-22 高親和性ｓｉｒｐ−アルファ試薬
JP2020084303A Active JP6918179B2 (ja) 2012-01-17 2020-05-13 高親和性ｓｉｒｐ−アルファ試薬
JP2021119529A Withdrawn JP2021176873A (ja) 2012-01-17 2021-07-20 高親和性ｓｉｒｐ−アルファ試薬

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017134728A Active JP6742279B2 (ja) 2012-01-17 2017-07-10 高親和性ｓｉｒｐ−アルファ試薬
JP2019151758A Active JP6783361B2 (ja) 2012-01-17 2019-08-22 高親和性ｓｉｒｐ−アルファ試薬
JP2020084303A Active JP6918179B2 (ja) 2012-01-17 2020-05-13 高親和性ｓｉｒｐ−アルファ試薬
JP2021119529A Withdrawn JP2021176873A (ja) 2012-01-17 2021-07-20 高親和性ｓｉｒｐ−アルファ試薬

Country Status (19)

Country Link
US (4) US9944911B2 (enExample)
EP (2) EP3766511A1 (enExample)
JP (5) JP6460796B2 (enExample)
CN (2) CN104136037B (enExample)
AU (1) AU2013209736C1 (enExample)
CA (1) CA2861307C (enExample)
CY (1) CY1123419T1 (enExample)
DK (1) DK2804617T3 (enExample)
ES (1) ES2816647T3 (enExample)
HK (1) HK1253217A1 (enExample)
HR (1) HRP20201285T1 (enExample)
HU (1) HUE050875T2 (enExample)
LT (1) LT2804617T (enExample)
PL (1) PL2804617T3 (enExample)
PT (1) PT2804617T (enExample)
RS (1) RS60606B1 (enExample)
SI (1) SI2804617T1 (enExample)
SM (1) SMT202000689T1 (enExample)
WO (1) WO2013109752A1 (enExample)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136037B (zh) * 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
HRP20191500T1 (hr) 2012-02-06 2019-11-29 Inhibrx Inc Protutijela protiv cd47 i postupci njihove upotrebe
DK2931752T3 (da) * 2012-12-17 2019-11-18 Trillium Therapeutics Inc Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner
AU2014238105B2 (en) 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
ES2898627T3 (es) * 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
WO2015041987A1 (en) * 2013-09-18 2015-03-26 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
WO2015161267A2 (en) 2014-04-18 2015-10-22 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd99
ES2819451T3 (es) 2014-08-08 2021-04-16 Univ Leland Stanford Junior Agentes PD-1 de alta afinidad y procedimientos de uso
CN113621075B (zh) * 2014-08-08 2024-09-20 Alx肿瘤生物技术公司 SIRP-α变体构建体及其用途
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
EP3188758B1 (en) 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
LT3180363T (lt) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai
EP4257145B1 (en) 2014-08-26 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
CA2958898A1 (en) * 2014-09-15 2016-03-24 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
CA2959821C (en) 2014-10-24 2024-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
US10864268B2 (en) * 2014-11-18 2020-12-15 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
EP3240569A4 (en) * 2014-12-30 2018-05-30 Celgene Corporation Anti-cd47 antibodies and uses thereof
EP3261671B1 (en) 2015-02-27 2020-10-21 The Board of Trustees of the Leland Stanford Junior University Combination therapy for treatment of atherosclerosis
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
WO2016179399A1 (en) * 2015-05-06 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University High affinity cd47 analogs
DK3298043T3 (da) * 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
IL294679B2 (en) 2015-08-07 2023-10-01 Alx Oncology Inc Structures with a SIRP-alpha site or its variant
BR102016018074A2 (pt) * 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
CN115569192A (zh) 2015-12-11 2023-01-06 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
CN114716552B (zh) 2016-01-11 2024-05-24 四十七公司 人源化、小鼠或嵌合抗cd47单克隆抗体
EP4438626A3 (en) 2016-04-14 2024-12-04 OSE Immunotherapeutics New anti-sirpa antibodies and their therapeutic applications
US11472878B2 (en) 2016-04-15 2022-10-18 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
US11649284B2 (en) 2016-04-18 2023-05-16 Baylor College Of Medicine Cancer gene therapy targeting CD47
CA3019841A1 (en) 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the prevention and treatment of surgical adhesions
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA
US10148939B2 (en) 2016-07-19 2018-12-04 Gopro, Inc. Mapping of spherical image data into rectangular faces for transport and decoding across networks
ES2987333T3 (es) * 2016-10-26 2024-11-14 Univ Leland Stanford Junior Regiones bisagra de inmunoglobulina modificadas para reducir la hemaglutinación
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
WO2018081897A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
EP3563835A4 (en) * 2016-12-29 2020-12-30 Korea Institute of Science and Technology NEW EXOSOME-BASED ANTI-CANCER AGENT
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
CN110913875A (zh) 2017-01-06 2020-03-24 同生运营公司 程序化以在肿瘤细胞中产生免疫调节子和抗癌治疗剂的微生物
WO2018140940A1 (en) 2017-01-30 2018-08-02 The Board Of Trustees Of The Leland Stanford Junior University A non-genotoxic conditioning regimen for stem cell transplantation
US11286301B2 (en) * 2017-02-28 2022-03-29 The Board Of Trustees Of The Leland Stanford Junior University Antifibrotic activity of CD47 blockade
US11078272B2 (en) 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
CN117065013A (zh) 2017-06-21 2023-11-17 小利兰·斯坦福大学托管委员会 针对血液恶性肿瘤的cd47靶向疗法的给药参数
WO2019014391A1 (en) 2017-07-12 2019-01-17 Synlogic Operating Company, Inc. MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNOMODULATORS AND ANTICANCER THERAPEUTIC AGENTS IN TUMOR CELLS
AU2018312222B2 (en) 2017-08-02 2024-11-21 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
US11529425B2 (en) 2017-09-07 2022-12-20 Dingfu Biotarget Co., Ltd. Immunoconjugates comprising signal regulatory protein alpha
WO2019061012A1 (zh) * 2017-09-26 2019-04-04 南京凯地生物科技有限公司 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
WO2019073080A1 (en) 2017-10-13 2019-04-18 Ose Immunotherapeutics ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF
CN111247172B (zh) 2017-10-18 2023-11-14 四十七公司 基于抗cd47剂的卵巢癌疗法
CA3080640C (en) 2017-11-06 2024-04-09 Trillium Therapeutics Inc. Cd47 blockade with radiation therapy
CA3083946A1 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
WO2019109357A1 (zh) * 2017-12-08 2019-06-13 杭州翰思生物医药有限公司 抗pd-1/cd47的双特异性抗体及其应用
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
CN108484774B (zh) * 2018-03-09 2021-11-05 上海高菲生物科技有限公司 一种SIRPα融合蛋白及其制备方法和用途
CN111936167A (zh) * 2018-03-13 2020-11-13 延龄草治疗公司 Egfr抗体对cd47阻断疗法的改善
KR20210006338A (ko) 2018-03-13 2021-01-18 오제 이뮈노테라프틱스 항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
CN108872569A (zh) * 2018-06-19 2018-11-23 浠思（上海）生物技术有限公司 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法
BR112020023322A2 (pt) 2018-07-10 2021-02-02 National University Corporation Kobe University anticorpo anti-sirpalfa
SG11202013167UA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
CN112543767B (zh) 2018-07-11 2024-05-31 卡尔医学有限公司 Pd1-4-1bbl变体融合蛋白及其使用方法
KR102129522B1 (ko) * 2018-07-26 2020-07-02 한국과학기술연구원 암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물
JP2021534769A (ja) 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
WO2020047651A1 (en) 2018-09-04 2020-03-12 Trillium Therapeutics Inc. Cd47 blockade with parp inhibition for disease treatment
CN109306017B (zh) * 2018-10-12 2021-02-09 倍而达药业（苏州）有限公司 一种基于SIRP-αD1突变体制备的重组蛋白及应用
BR112021008908A2 (pt) * 2018-11-07 2021-08-17 Daiichi Sankyo Company, Limited método para melhorar a cinética do peptídeo no sangue
CN111303293B (zh) 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
US20220289821A1 (en) * 2018-11-29 2022-09-15 Trillium Therapeutics Inc Biomarkers for cd47 blockade therapy
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
JP7680032B2 (ja) 2019-03-18 2025-05-20 ラディック インスティテュート フォア キャンサー リサーチ リミテッド Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用
CN119700933A (zh) 2019-05-31 2025-03-28 Alx肿瘤生物技术公司 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
EP3980747A1 (en) 2019-06-07 2022-04-13 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2020257196A1 (en) * 2019-06-17 2020-12-24 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating infections by blocking pathogen mimics of cd47
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20230220342A1 (en) * 2020-04-24 2023-07-13 Georgia State University Research Foundation, Inc. SIRPa Deficient Macrophages for Treating Cancer
JP2023528341A (ja) * 2020-06-01 2023-07-04 エーエルエックス オンコロジー インコーポレイテッド 低メチル化剤を含むがんを治療するための併用療法
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022010806A1 (en) 2020-07-06 2022-01-13 ALX Oncology Inc. Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
CN114057888A (zh) * 2020-07-30 2022-02-18 三生国健药业（上海）股份有限公司 一种SIRPα-Fc融合蛋白
JP7446953B2 (ja) * 2020-08-27 2024-03-11 株式会社三共 遊技機
KR102557016B1 (ko) * 2020-09-22 2023-07-20 비피진 주식회사 암 치료를 위한 cd47 바인더 및 리포좀 복합체
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4329520A1 (en) 2021-04-27 2024-03-06 Pfizer Inc. Enhancement of cd47 blockade therapy with dhfr inhibitors
AU2022273727A1 (en) 2021-05-13 2023-11-09 ALX Oncology Inc. Combination therapies for treating cancer
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023003331A1 (en) * 2021-07-19 2023-01-26 Yuhan Corporation Sirp-alpha variants and use thereof
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
US20250235504A1 (en) 2021-10-29 2025-07-24 Pfizer Inc. Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
CN118139874A (zh) * 2021-11-01 2024-06-04 山东先声生物制药有限公司 SIRPa突变体及其应用
WO2023079438A1 (en) 2021-11-08 2023-05-11 Pfizer Inc. Enhancement of cd47 blockade therapy with anti-vegf agents
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
KR20240117080A (ko) * 2021-12-21 2024-07-31 에프비디 바이올로직스 리미티드 조작된 SIRPα 변이체 및 이의 사용 방법
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
US20250051441A1 (en) * 2021-12-23 2025-02-13 Fbd Biologics Limited Cd47/4-1bb-targeting protein complex and methods of use thereof
IL314210A (en) * 2022-01-18 2024-09-01 Fbd Biologics Ltd CD47/PD-L1-targeted protein complex and methods of using it
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
US12358887B2 (en) 2022-03-17 2025-07-15 Gilead Sciences, Inc. IKAROS Zinc Finger Family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
IL315706A (en) 2022-03-24 2024-11-01 Bitterroot Bio Inc Sirp-alpha fusion polypeptides with modified fc domains
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
US20250257113A1 (en) * 2022-03-24 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Multivalent sirp-alpha fusion polypeptides
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
AU2023263628A1 (en) * 2022-05-06 2024-12-19 Biosion Inc. Recombinant fusion protein targeting cd40 and cd47
WO2023228044A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Dosing regimens of sirp alpha fusion proteins for treatment of cancer
JP2025523369A (ja) 2022-06-01 2025-07-23 エーエルエックス オンコロジー インコーポレイテッド 尿路上皮癌腫を治療するための併用療法
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
WO2024015634A2 (en) * 2022-07-15 2024-01-18 Nutcracker Therapeutics, Inc. Mrna therapies including sirp-alpha
WO2024040151A1 (en) 2022-08-18 2024-02-22 Pfizer Inc. Sirp alpha fusion protein and anti-cd38 antibody combination therapies
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4630121A1 (en) 2022-12-09 2025-10-15 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
TW202440151A (zh) 2022-12-09 2024-10-16 美商輝瑞大藥廠 Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024193635A1 (en) * 2023-03-22 2024-09-26 Wangzhi LI Sirp variants and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
TW202511298A (zh) * 2023-05-31 2025-03-16 香港商Ｆｂｄ生物製劑有限公司 靶向ｃｄ４７／ｐｄ—ｌ１之蛋白質複合物及其使用方法
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541615B1 (en) * 1996-11-15 2003-04-01 Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
JP2003502062A (ja) * 1999-06-11 2003-01-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
AU2003264100A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CA2747678A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
PL2429574T3 (pl) * 2009-05-15 2015-12-31 Univ Health Network Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie SIRP-CD47
CN104136037B (zh) * 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
EP4257145B1 (en) * 2014-08-26 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
ES2894335T5 (es) * 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
KR102024554B1 (ko) * 2018-02-26 2019-09-24 엘지전자 주식회사 유도 가열 장치 및 유도 가열 장치의 제어 방법

Also Published As

Publication number Publication date
US20250223355A1 (en) 2025-07-10
LT2804617T (lt) 2020-09-10
AU2013209736B2 (en) 2017-09-07
US11208481B2 (en) 2021-12-28
HRP20201285T1 (hr) 2020-11-13
EP2804617B9 (en) 2021-04-07
US20180195054A1 (en) 2018-07-12
HK1201757A1 (en) 2015-09-11
JP2018021016A (ja) 2018-02-08
PT2804617T (pt) 2020-09-10
CN104136037A (zh) 2014-11-05
CN107880100A (zh) 2018-04-06
CA2861307A1 (en) 2013-07-25
CY1123419T1 (el) 2021-12-31
CA2861307C (en) 2021-05-25
ES2816647T3 (es) 2021-04-05
PL2804617T3 (pl) 2020-11-30
RS60606B1 (sr) 2020-08-31
EP2804617A1 (en) 2014-11-26
EP2804617B1 (en) 2020-06-24
EP2804617A4 (en) 2015-11-25
WO2013109752A1 (en) 2013-07-25
EP3766511A1 (en) 2021-01-20
JP2015504899A (ja) 2015-02-16
HK1253217A1 (zh) 2019-06-14
US12195532B2 (en) 2025-01-14
JP2020007329A (ja) 2020-01-16
AU2013209736C1 (en) 2017-12-14
JP6742279B2 (ja) 2020-08-19
SI2804617T1 (sl) 2020-10-30
US20150071905A1 (en) 2015-03-12
SMT202000689T1 (it) 2021-01-05
CN104136037B (zh) 2018-02-23
JP2021176873A (ja) 2021-11-11
JP6918179B2 (ja) 2021-08-11
JP2020143104A (ja) 2020-09-10
HUE050875T2 (hu) 2021-01-28
AU2013209736A1 (en) 2014-08-07
US20220064293A1 (en) 2022-03-03
US9944911B2 (en) 2018-04-17
JP6783361B2 (ja) 2020-11-11
DK2804617T3 (da) 2020-08-10

Similar Documents

Publication Publication Date Title
JP6918179B2 (ja) 高親和性ｓｉｒｐ−アルファ試薬
US10358472B2 (en) High affinity CD47 analogs
CN109311997A (zh) 抗axl拮抗抗体
JP2018510613A (ja) 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）抗体およびその派生使用
CN116096753A (zh) 对abcb5具有特异性的抗体及其用途
US20200330591A1 (en) Treatment
HK40043038A (en) High affinity sirp-alpha reagents
HK1201757B (en) High affinity sirp-alpha reagents
CN118725133A (zh) 双特异性抗体及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170818

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20171020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181225

R150 Certificate of patent or registration of utility model

Ref document number: 6460796

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250